CD20 x CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting

被引：8
|
作者：
Liu, Xinyuan [1 ]
Zhao, Juanjuan [2 ]
Guo, Xiangqian [1 ]
Song, Yongping [2 ]
机构：
[1] Henan Univ, Inst Biomed Informat, Bioinformat Ctr, Henan Prov Engn Ctr Tumor Mol Med,Sch Basic Med Sc, Kaifeng 475004, Henan, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Hematol, Zhengzhou 450052, Henan, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2023年 / 16卷 / 01期
关键词：
Non-Hodgkin's lymphoma; Bispecific antibody; CD20; CD3; EPCORE NHL-1;
D O I：
10.1186/s13045-023-01488-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 x CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20(+) NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 x CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023).
引用
收藏
页数：4
相关论文
共 50 条
  • [1] CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
    Xinyuan Liu
    Juanjuan Zhao
    Xiangqian Guo
    Yongping Song
    Journal of Hematology & Oncology, 16
  • [2] Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting
    Jin, Shenhe
    Liu, Yi
    Zhang, Ye
    Zhou, Fengping
    You, Liangshun
    Zhang, Jin
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14
  • [3] Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases
    Huang, Hongpeng
    Wei, Xuetao
    RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2025, 5 (04): : 209 - 216
  • [4] Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
    Jiangxue Hou
    Yufu Li
    Quande Lin
    Experimental Hematology & Oncology, 12
  • [5] Disseminated Mycobacterium avium Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma
    Little, Jessica S.
    Hurtado, Rocio M.
    Boire, Nicholas
    Baden, Lindsey R.
    Laga, Alvaro C.
    Silk, Ann W.
    Jacobson, Caron A.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (09):
  • [6] Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
    Hou, Jiangxue
    Li, Yufu
    Lin, Quande
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [7] Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting
    Li, Xingchen
    Zhang, Peng
    Sun, Hao
    Han, Lijie
    Jiang, Zhongxing
    Yu, Jifeng
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (12) : 1193 - 1195
  • [8] Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
    Zhao, Juanjuan
    Ren, Quan
    Liu, Xinyuan
    Guo, Xiangqian
    Song, Yongping
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [9] Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
    Juanjuan Zhao
    Quan Ren
    Xinyuan Liu
    Xiangqian Guo
    Yongping Song
    Journal of Hematology & Oncology, 16
  • [10] Development of human bispecific antibodies against CD20/CD55 or CD20/CD59 for the treatment of Burkitt lymphoma
    Macor, P.
    Secco, E.
    Mezzaroba, N.
    De Maso, L.
    Durigutto, P.
    Gaiotto, T.
    Garrovo, C.
    Biffi, F.
    Zorzet, S.
    Sblattero, D.
    Tedesco, F.
    MOLECULAR IMMUNOLOGY, 2010, 47 (13) : 2287 - 2287
12345